九月 09, 2020

Deal Drivers in Healthcare and Life Sciences Mainland China: M&A and IPO Trends in H1 2020 and beyond

Virtual briefing in partnership with Mergermarket, an Acuris company

DATE: 9 September 2020

TIME: 11:00 Beijing

Not only the cause for the most profound economic crisis since the Global Financial Crisis, but COVID-19 was also a wake-up call to better prepare for global pandemics and public health emergencies. After several years’ growth in the Greater China region, Healthcare and life science sector are firm back under the spotlight, as being one of the most resilient industries in investment and M&A.

  • Unlike the M&A slump in major traditional sectors, biotech in China and Hong Kong enjoyed a 78% year-on-year growth in M&A deal value in 1H 2020, as well as being the most robust subsector to recover in 2Q
  • The biotech listing boom in HKEX remains and was further fueled by dual-listing candidates from NYSE or Shanghai’s STAR board. Pharma, Medical and Biotech together recorded 67 deals worth USD 6.9bn in 1H

In this live panel discussion with China Everbright, I-Mab and Fangda Partners we take stock of M&A and IPOs in Mainland China and consider the areas where financial stress is of greatest concern, as well as opportunities to be sought after.

Unable to join the live session? Register now to access the on-demand replay after the webinar.

 

ACCESS WEBINAR